| Document Date: 2014-11-03 11:26:21
Open Document File Size: 171,17 KBShare Result on Facebook
City Osaka / Washington / DC / / Company AEs / Shionogi & Co. Ltd. / ViiV Healthcare Ltd. / Financial review / GlaxoSmithKline / Pfizer Inc. / HIV/AIDS / Japan Shionogi & Co. / ViiV Healthcare LLC / Shionogi Inc. / / Event M&A / Business Partnership / / IndustryTerm in‐line products / research‐driven pharmaceutical / integrase inhibitor / HIV treatment / pharmaceuticals / treatment of HIV / foreign healthcare reforms / with respect to product / / MedicalCondition HIV / headache / nausea / cancer / disease / nasopharyngitis / allergy / Metabolic Syndrome / AIDS / Infectious Diseases / infection / chronic infection / / Person Tsutae "Den" Nagata / John Pottage / Marc Meachem Melinda Stubbee Sally / Camilla Bull / Jeff McLaughlin Tom Curry / Gary Davies Ziba Shamsi / / / Position investigator / Chief Medical Officer / Medical Officer / Analyst / forward / Private / Chief / / Product abacavir / lamivudine / / ProgrammingLanguage DC / / URL www.shionogi.co.jp / www.shionogi.com / www.viivhealthcare.com / /
SocialTag |
Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1